Biogen (BIIB) falls as earnings, revenue misses consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. RTX
8. SMCI
9. GOOGL
10. S

Go back to Biogen (BIIB) falls as earnings, revenue misses consensus

Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia

February 12, 2024 4:06 PM EST

Friedreichs ataxia is a rare, genetic, life-shortening, debilitating, and neurodegenerative disorderTreatment with SKYCLARYS improved patient function compared to placeboBiogen is leveraging its expertise and capabilities in rare disease to bring this groundbreaking treatment to patients

CAMBRIDGE, Mass., Feb. 12, 2024 (GLOBE NEWSWIRE) --  Biogen Inc. (Nasdaq: BIIB) announced the European Commission (EC) has authorized SKYCLARYS® (omaveloxolone) for the treatment of Friedreichs... More

Aptar Signs Enterprise Agreement with Biogen to Operate and Develop Digital Health Solutions

February 9, 2024 10:00 AM EST

New partnership model leverages Aptar Digital Healths capabilities to support the development and operation of new and existing digital health solutions globally Initial scope of multi-year agreement covers several indications in neurology and immunology across 15 countries

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)-- Aptar Digital Health, part of AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, has entered into an enterprise agreement with Biogen Inc. (Nasdaq: BIIB) to operate and... More